Latest Safety News

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet the company progresses its climate ambitions with the successful start-up of the Moomba CCS project and strong emissions reductions.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% revenue decline, offset by progress in carbon capture and storage projects and emissions reductions. The company maintains a strong balance sheet while setting ambitious climate targets.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet the company progresses its climate ambitions with the successful Moomba CCS project and robust decarbonisation efforts.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

St Barbara Limited reports a strong quarter with Simberi gold production up 37% and a robust US$235 million expansion plan, while navigating a critical tax assessment review in Papua New Guinea.

RemSense Technologies reported a cash flow positive Q3 FY2025 with $420K net cash from operations and $1.403M in customer receipts, underpinned by renewed contracts and strategic partnerships across energy and industrial sectors.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

PVW Resources reports strong drilling results at its Capão Bonito rare earth project in Brazil, with Total Rare Earth Oxide grades reaching up to 3,267 ppm, while preparing for further exploration campaigns across its Brazilian hubs.

Burley Minerals has completed maiden drilling at its Cane Bore Iron Project with assay results due soon, while securing $1 million in fresh capital to accelerate exploration in Western Australia’s Pilbara region.